7-octadecynoic acid is a lipid of Fatty Acyls (FA) class.
We collected disease MeSH terms mapped to the references associated with 7-octadecynoic acid
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Khosla S | Magic bullets to kill nasty osteoclasts. | 2005 | Endocrinology | pmid:16009971 |
Feng X | RANKing intracellular signaling in osteoclasts. | 2005 | IUBMB Life | pmid:16012047 |
Stenman UH et al. | Prognostic value of serum markers for prostate cancer. | 2005 | Scand J Urol Nephrol Suppl | pmid:16019759 |
Li J et al. | [Effect of raloxifene and estradiol on the biological function and osteoprotegerin expression of osteoblasts in vitro]. | 2005 | Di Yi Jun Yi Da Xue Xue Bao | pmid:16027068 |
Pipes GD et al. | Optimization and applications of CDAP labeling for the assignment of cysteines. | 2005 | Pharm. Res. | pmid:16028006 |
Yang S et al. | Muramyl dipeptide enhances osteoclast formation induced by lipopolysaccharide, IL-1 alpha, and TNF-alpha through nucleotide-binding oligomerization domain 2-mediated signaling in osteoblasts. | 2005 | J. Immunol. | pmid:16034140 |
Deschner J et al. | Regulation of RANKL by biomechanical loading in fibrochondrocytes of meniscus. | 2006 | J Biomech | pmid:16038916 |
Guang-da X et al. | Changes in plasma concentrations of osteoprotegerin before and after levothyroxine replacement therapy in hypothyroid patients. | 2005 | J. Clin. Endocrinol. Metab. | pmid:16046585 |
Kazama JJ et al. | Maxacalcitol therapy decreases circulating osteoprotegerin levels in dialysis patients with secondary hyperparathyroidism. | 2005 | Clin. Nephrol. | pmid:16047647 |
Zahanich I et al. | Molecular and functional expression of voltage-operated calcium channels during osteogenic differentiation of human mesenchymal stem cells. | 2005 | J. Bone Miner. Res. | pmid:16059635 |
Cao JJ et al. | Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse. | 2005 | J. Bone Miner. Res. | pmid:16059637 |
Terpos E et al. | The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL/osteoprotegerin ratio. | 2005 | Leukemia | pmid:16079895 |
Huang P et al. | [In vitro study of combination rhOPG-Fc and alendronate on inhibition osteoclast]. | 2005 | Zhonghua Wai Ke Za Zhi | pmid:16083587 |
Kwon OH et al. | The hematopoietic transcription factor PU.1 regulates RANK gene expression in myeloid progenitors. | 2005 | Biochem. Biophys. Res. Commun. | pmid:16083856 |
Hayton MJ et al. | Involvement of adenosine 5'-triphosphate in ultrasound-induced fracture repair. | 2005 | Ultrasound Med Biol | pmid:16085103 |
von Knoch F et al. | Suppression of polyethylene particle-induced osteolysis by exogenous osteoprotegerin. | 2005 | J Biomed Mater Res A | pmid:16088891 |
Ashcroft AJ and Carding SR | RANK ligand and osteoprotegerin: emerging roles in mucosal inflammation. | 2005 | Gut | pmid:16099805 |
Zojer N et al. | Bisphosphonate treatment does not affect serum levels of osteoprotegerin and RANKL in hypercalcemic cancer patients. | 2005 Sep-Oct | Anticancer Res. | pmid:16101188 |
Lems WF and Bijlsma JW | [Clinical implications of new insights into the regulation of bone resorption]. | 2005 | Ned Tijdschr Geneeskd | pmid:16104110 |
Daroszewska A and Ralston SH | Genetics of Paget's disease of bone. | 2005 | Clin. Sci. | pmid:16104845 |
Rogers A and Eastell R | Circulating osteoprotegerin and receptor activator for nuclear factor kappaB ligand: clinical utility in metabolic bone disease assessment. | 2005 | J. Clin. Endocrinol. Metab. | pmid:16105967 |
Wise GE et al. | CSF-1 regulation of osteoclastogenesis for tooth eruption. | 2005 | J. Dent. Res. | pmid:16109994 |
Yang KC et al. | [Effect of nylestriol and levonorgestrel on the expression of Opg/OPGL in human osteosarcoma MG-63 cell lines]. | 2004 | Zhong Nan Da Xue Xue Bao Yi Xue Ban | pmid:16114553 |
Ziegler S et al. | Osteoprotegerin plasma concentrations correlate with severity of peripheral artery disease. | 2005 | Atherosclerosis | pmid:16115489 |
Gonnelli S et al. | Osteoprotegerin (OPG) and receptor activator of NF-kB ligand (RANK-L) serum levels in patients on chronic hemodialysis. | 2005 | J. Endocrinol. Invest. | pmid:16117195 |
Zhou Z et al. | Zoledronic acid inhibits primary bone tumor growth in Ewing sarcoma. | 2005 | Cancer | pmid:16121404 |
Avignon A et al. | Osteoprotegerin is associated with silent coronary artery disease in high-risk but asymptomatic type 2 diabetic patients. | 2005 | Diabetes Care | pmid:16123486 |
Kusumi A et al. | Regulation of synthesis of osteoprotegerin and soluble receptor activator of nuclear factor-kappaB ligand in normal human osteoblasts via the p38 mitogen-activated protein kinase pathway by the application of cyclic tensile strain. | 2005 | J. Bone Miner. Metab. | pmid:16133687 |
Deftos LJ | Treatment of Paget's disease--taming the wild osteoclast. | 2005 | N. Engl. J. Med. | pmid:16135831 |
Cundy T et al. | Recombinant osteoprotegerin for juvenile Paget's disease. | 2005 | N. Engl. J. Med. | pmid:16135836 |
Su X et al. | [Effects of parathyroid hormone on osteoprotegerin expression and osteoprotegerin ligand and their related cytokines in human osteoblasts]. | 2004 | Zhong Nan Da Xue Xue Bao Yi Xue Ban | pmid:16137047 |
Heinrich J et al. | CSF-1, RANKL and OPG regulate osteoclastogenesis during murine tooth eruption. | 2005 | Arch. Oral Biol. | pmid:16137499 |
Moschen AR et al. | The RANKL/OPG system and bone mineral density in patients with chronic liver disease. | 2005 | J. Hepatol. | pmid:16143421 |
Yang YQ et al. | Human periodontal ligament cells express osteoblastic phenotypes under intermittent force loading in vitro. | 2006 | Front. Biosci. | pmid:16146769 |
Takahashi N et al. | [Osteoprotegerin (OPG)]. | 2005 | Nippon Rinsho | pmid:16149650 |
Choi JY et al. | Genetic polymorphisms of OPG, RANK, and ESR1 and bone mineral density in Korean postmenopausal women. | 2005 | Calcif. Tissue Int. | pmid:16151677 |
Viereck V et al. | Atorvastatin stimulates the production of osteoprotegerin by human osteoblasts. | 2005 | J. Cell. Biochem. | pmid:16152630 |
Crisafulli A et al. | Osteoprotegerin and bone mineral density in hemodiafiltration patients. | 2005 | Ren Fail | pmid:16152990 |
Lau YS et al. | Phenotypic and molecular studies of giant-cell tumors of bone and soft tissue. | 2005 | Hum. Pathol. | pmid:16153456 |
Zhou YQ et al. | [OPG and OPGL expression in condyle cartilage of temporomandibular joint following anterior disc displacement]. | 2005 | Shanghai Kou Qiang Yi Xue | pmid:16155701 |
Holen I et al. | Osteoprotegerin (OPG) expression by breast cancer cells in vitro and breast tumours in vivo--a role in tumour cell survival? | 2005 | Breast Cancer Res. Treat. | pmid:16155791 |
Hong JS et al. | Maternal plasma osteoprotegerin concentration in normal pregnancy. | 2005 | Am. J. Obstet. Gynecol. | pmid:16157103 |
Raustyte G et al. | Calcium deposition and expression of bone modelling markers in the tympanic membrane following acute otitis media. | 2006 | Int. J. Pediatr. Otorhinolaryngol. | pmid:16159670 |
Stolina M et al. | RANKL is a marker and mediator of local and systemic bone loss in two rat models of inflammatory arthritis. | 2005 | J. Bone Miner. Res. | pmid:16160733 |
Yasuda H | [OPG, anti-rANKL antibody]. | 2005 | Nippon Rinsho | pmid:16164225 |
Ueland T and Bollerslev J | Bone metabolism and growth hormone deficiency. Experimental and clinical aspects. | 2005 | Front Horm Res | pmid:16166760 |
Ulrich-Vinther M et al. | Gene therapy with human osteoprotegerin decreases callus remodeling with limited effects on biomechanical properties. | 2005 | Bone | pmid:16169783 |
Hjertner Ø et al. | Identification of new targets for therapy of osteolytic bone disease in multiple myeloma. | 2005 | Curr Drug Targets | pmid:16178802 |
Nardelli B et al. | Osteostat/tumor necrosis factor superfamily 18 inhibits osteoclastogenesis and is selectively expressed by vascular endothelial cells. | 2006 | Endocrinology | pmid:16179414 |
Kostenuik PJ | Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength. | 2005 | Curr Opin Pharmacol | pmid:16188502 |
Sakakura Y et al. | Immunolocalization of receptor activator of nuclear factor-kappaB ligand (RANKL) and osteoprotegerin (OPG) in Meckel's cartilage compared with developing endochondral bones in mice. | 2005 | J. Anat. | pmid:16191162 |
Meng XM et al. | [Expression of receptor activator of NF-kappa B ligand and osteoprotegerin protein in the giant cell lesions of jaw]. | 2005 | Zhonghua Kou Qiang Yi Xue Za Zhi | pmid:16191370 |
Tabuchi M et al. | Enhancement of crude bone morphogenetic protein-induced new bone formation and normalization of endochondral ossification by bisphosphonate treatment in osteoprotegerin-deficient mice. | 2005 | Calcif. Tissue Int. | pmid:16193235 |
Otsuka T et al. | Enamel matrix derivative promotes osteoclast cell formation by RANKL production in mouse marrow cultures. | 2005 | J Dent | pmid:16199283 |
Neumann E et al. | The RANK/RANKL/osteoprotegerin system in rheumatoid arthritis: new insights from animal models. | 2005 | Arthritis Rheum. | pmid:16200575 |
Liu D et al. | Chronology and regulation of gene expression of RANKL in the rat dental follicle. | 2005 | Eur. J. Oral Sci. | pmid:16202028 |
Xie F et al. | Increase in bone mass and bone strength by Sambucus williamsii HANCE in ovariectomized rats. | 2005 | Biol. Pharm. Bull. | pmid:16204939 |
Juarranz Y et al. | Protective effect of vasoactive intestinal peptide on bone destruction in the collagen-induced arthritis model of rheumatoid arthritis. | 2005 | Arthritis Res. Ther. | pmid:16207319 |
Görtz B et al. | Tumour necrosis factor activates the mitogen-activated protein kinases p38alpha and ERK in the synovial membrane in vivo. | 2005 | Arthritis Res. Ther. | pmid:16207331 |
Pantsulaia I et al. | Contribution of the familial and genetic factors on monocyte chemoattractant protein-1 variation in healthy human pedigrees. | 2005 | Cytokine | pmid:16213155 |
Low E et al. | Expression of mRNA for osteoprotegerin and receptor activator of nuclear factor kappa beta ligand (RANKL) during root resorption induced by the application of heavy orthodontic forces on rat molars. | 2005 | Am J Orthod Dentofacial Orthop | pmid:16214633 |
Schneeweis LA et al. | Functional dissection of osteoprotegerin and its interaction with receptor activator of NF-kappaB ligand. | 2005 | J. Biol. Chem. | pmid:16215261 |
Bezerra MC et al. | Low bone density and low serum levels of soluble RANK ligand are associated with severe arterial calcification in patients with Takayasu arteritis. | 2005 | Rheumatology (Oxford) | pmid:16219645 |
Minenna G et al. | [RANKL/RANK, OPG and OPT in a group of patients affected by chronic arthritis. Preliminary report]. | 2005 | Recenti Prog Med | pmid:16229324 |
Zwerina J et al. | Heme oxygenase 1 (HO-1) regulates osteoclastogenesis and bone resorption. | 2005 | FASEB J. | pmid:16234431 |
Viereck V et al. | Isopropanolic extract of black cohosh stimulates osteoprotegerin production by human osteoblasts. | 2005 | J. Bone Miner. Res. | pmid:16234977 |
Gajewska J et al. | [The impairement of bone formation and resorption in 25-year-old man with neglected celiac disease]. | 2005 | Wiad. Lek. | pmid:16238129 |
Ruocco MG and Karin M | IKK{beta} as a target for treatment of inflammation induced bone loss. | 2005 | Ann. Rheum. Dis. | pmid:16239395 |
Anandarajah AP and Schwarz EM | Anti-RANKL therapy for inflammatory bone disorders: Mechanisms and potential clinical applications. | 2006 | J. Cell. Biochem. | pmid:16240334 |
Palma MA and Body JJ | Usefulness of bone formation markers in breast cancer. | 2005 Jul-Sep | Int. J. Biol. Markers | pmid:16240842 |
Hsu YH et al. | Variation in genes involved in the RANKL/RANK/OPG bone remodeling pathway are associated with bone mineral density at different skeletal sites in men. | 2006 | Hum. Genet. | pmid:16249885 |
Palmqvist P et al. | Inhibition of hormone and cytokine-stimulated osteoclastogenesis and bone resorption by interleukin-4 and interleukin-13 is associated with increased osteoprotegerin and decreased RANKL and RANK in a STAT6-dependent pathway. | 2006 | J. Biol. Chem. | pmid:16251181 |
Xiao HL et al. | [Expression and activity determination of TNFR domain of osteoprotegerin in E.coli and corresponding antibody preparation]. | 2005 | Yi Chuan | pmid:16257908 |
Liu W et al. | Receptor activator of NF-kappaB (RANK) cytoplasmic motif, 369PFQEP373, plays a predominant role in osteoclast survival in part by activating Akt/PKB and its downstream effector AFX/FOXO4. | 2005 | J. Biol. Chem. | pmid:16260781 |
Yeung RS | Bones, blood vessels, and the immune system: what's the link? | 2005 | J. Rheumatol. | pmid:16265680 |
Simonini G et al. | Osteoprotegerin serum levels in Kawasaki disease: an additional potential marker in predicting children with coronary artery involvement. | 2005 | J. Rheumatol. | pmid:16265708 |
Tanaka H et al. | Nicotine and lipopolysaccharide stimulate the formation of osteoclast-like cells by increasing macrophage colony-stimulating factor and prostaglandin E2 production by osteoblasts. | 2006 | Life Sci. | pmid:16266722 |
Kim SM et al. | Serum osteoprotegerin levels are associated with inflammation and pulse wave velocity. | 2005 | Clin. Endocrinol. (Oxf) | pmid:16268814 |
Secchiero P et al. | Role of the RANKL/RANK system in the induction of interleukin-8 (IL-8) in B chronic lymphocytic leukemia (B-CLL) cells. | 2006 | J. Cell. Physiol. | pmid:16270354 |
Tarquini R et al. | Circasemidian rather than circadian variation of circulating osteoprotegerin in clinical health. | 2005 | Biomed. Pharmacother. | pmid:16275499 |
Cozzani M et al. | Transcription Factor Decoy (TFD) as a novel approach for the control of osteoclastic resorption. | 2005 | Prog Orthod | pmid:16276433 |
Gaudio A et al. | Hepatic osteodystrophy: does the osteoprotegerin/receptor activator of nuclear factor-kB ligand system play a role? | 2005 | J. Endocrinol. Invest. | pmid:16277162 |
Taubman MA et al. | Immune response: the key to bone resorption in periodontal disease. | 2005 | J. Periodontol. | pmid:16277573 |
Bartold PM et al. | Periodontitis and rheumatoid arthritis: a review. | 2005 | J. Periodontol. | pmid:16277578 |
Kaji H et al. | Statins modulate the levels of osteoprotegerin/receptor activator of NFkappaB ligand mRNA in mouse bone-cell cultures. | 2005 | Horm. Metab. Res. | pmid:16278780 |
Morena M et al. | Plasma osteoprotegerin is associated with mortality in hemodialysis patients. | 2006 | J. Am. Soc. Nephrol. | pmid:16280472 |
Kishimoto K et al. | Expression profile of genes related to osteoclastogenesis in mouse growth plate and articular cartilage. | 2006 | Histochem. Cell Biol. | pmid:16283360 |
Wise GE et al. | Injections of osteoprotegerin and PMA delay tooth eruption. | 2006 | Clin Anat | pmid:16283633 |
Cross SS et al. | Osteoprotegerin (OPG)--a potential new role in the regulation of endothelial cell phenotype and tumour angiogenesis? | 2006 | Int. J. Cancer | pmid:16287088 |
Schoppet M et al. | TNF-related apoptosis-inducing ligand and its decoy receptor osteoprotegerin in nonischemic dilated cardiomyopathy. | 2005 | Biochem. Biophys. Res. Commun. | pmid:16288714 |
Michael H et al. | Estrogen and testosterone use different cellular pathways to inhibit osteoclastogenesis and bone resorption. | 2005 | J. Bone Miner. Res. | pmid:16294275 |
Nicholls BM et al. | Limited rescue of osteoclast-poor osteopetrosis after successful engraftment by cord blood from an unrelated donor. | 2005 | J. Bone Miner. Res. | pmid:16294279 |
Andelković Z et al. | [Osteoprotegerin--a neutralizing receptor, protector of bones and a potential antiresorptive agent]. | 2005 Jul-Aug | Med. Pregl. | pmid:16296579 |
Hormdee D et al. | Protein kinase-A-dependent osteoprotegerin production on interleukin-1 stimulation in human gingival fibroblasts is distinct from periodontal ligament fibroblasts. | 2005 | Clin. Exp. Immunol. | pmid:16297161 |
Humphrey EL et al. | Effects of dissociated glucocorticoids on OPG and RANKL in osteoblastic cells. | 2006 | Bone | pmid:16298558 |
Geusens P and Reid D | Newer drug treatments: their effects on fracture prevention. | 2005 | Best Pract Res Clin Rheumatol | pmid:16301192 |
Hamdy NA | Osteoprotegerin as a potential therapy for osteoporosis. | 2005 | Curr Osteoporos Rep | pmid:16303111 |
Wiercinska-Drapalo A et al. | Transforming growth factor beta1 and prostaglandin E2 concentrations are associated with bone formation markers in ulcerative colitis patients. | 2005 | Prostaglandins Other Lipid Mediat. | pmid:16303613 |
Yang M et al. | Chemokine and chemokine receptor expression during colony stimulating factor-1-induced osteoclast differentiation in the toothless osteopetrotic rat: a key role for CCL9 (MIP-1gamma) in osteoclastogenesis in vivo and in vitro. | 2006 | Blood | pmid:16304045 |
Pettersen I et al. | Osteoprotegerin is expressed in colon carcinoma cells. | 2005 Nov-Dec | Anticancer Res. | pmid:16309167 |